Prosecution Insights
Prosecution Insights
11 pending office actions • 8 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 1 (9%) |
| §112 only | 2 (18%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 3 (27%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 1 | 24.9% | +48.9% |
| SHUPE, ELIZABETH A | 1 | 65.7% | +46.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| LEE, CHIHYI NMN | 1 | 32.9% | +58.5% |
| BROWE, DAVID | 1 | 26.2% | +27.7% |
| DENT, ALANA HARRIS | 1 | 44.3% | +32.1% |
| ISMAIL, REHANA | 1 | 77.3% | +32.8% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.3% | +8.0% |
| SHOWALTER, ALEXANDER KEITH | 1 | 53.6% | +32.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262236 | Methods of Cancer Treatment Using Anti-TIGIT Antibodies in Combination with Anti-PD1 Antibodies | DENT, ALANA HARRIS | 21d |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18431626 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | — |
| 18422518 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | DEKARSKE, MADELINE MCGUIRE | — |
| 18541928 | METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER | BROWE, DAVID | — |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262236 | Methods of Cancer Treatment Using Anti-TIGIT Antibodies in Combination with Anti-PD1 Antibodies | DENT, ALANA HARRIS | 21d |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18697500 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | — |
| 18431626 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | — |
| 18391154 | (R)-Glutarimide CRBN Ligands and Methods of Use | LEE, CHIHYI NMN | — |
| 18541928 | METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER | BROWE, DAVID | — |
| 18260654 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | ISMAIL, REHANA | — |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1622 | 1 |
| 1628 | 1 |
| 1617 | 1 |
| 1643 | 1 |
| 1623 | 1 |
| 1629 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — | §112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18697500 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | — | DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18431626 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | 1625 | §101§112Other | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18422518 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112DP | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18391154 | (R)-Glutarimide CRBN Ligands and Methods of Use | LEE, CHIHYI NMN | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18541928 | METHODS OF TREATING B-CELL PROLIFERATIVE DISORDER | BROWE, DAVID | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18262236 | Methods of Cancer Treatment Using Anti-TIGIT Antibodies in Combination with Anti-PD1 Antibodies | DENT, ALANA HARRIS | 1643 | §102§103Other | Non-Final OA | 21d | Pending | Jul 20, 2023 |
| 18260654 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | ISMAIL, REHANA | 1625 | — | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18260649 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112 | Final Rejection | — | Pending | May 19, 2023 |
| 17802111 | METHODS OF TREATING DLBCL USING BTK INHIBITORS AND COMBINATIONS THEREOF | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | — | Pending | Aug 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial